Elevated
low-density lipoprotein (
LDL)-cholesterol is associated with a significantly increased risk of
coronary heart disease but lowering
LDL-cholesterol to levels established in current National
Cholesterol Education Program (NCEP) guidelines provides significant risk reduction. Nevertheless, many patients receiving
lipid-lowering
therapy, particularly those at highest
coronary heart disease risk, do not reach
LDL-cholesterol goals with their current medications.
Ezetimibe (
Zetia, Merck Schering-Plough) is the first of a new class of
lipid-lowering drugs known as
cholesterol absorption inhibitors.
Ezetimibe has a favorable pharmacokinetic profile, which allows it to be administered once daily and to be given in conjunction with
statins. In a series of randomized, controlled, multicenter studies,
ezetimibe produced significant improvements in levels of
LDL-cholesterol and other
lipid parameters when used as monotherapy, with a safety profile comparable with that of placebo. Furthermore, coadministration of
ezetimibe with a
statin (
simvastatin,
atorvastatin,
lovastatin, or
pravastatin) was more effective than
statin monotherapy in lowering
LDL-cholesterol and improving other
lipid parameters. Moreover, coadministration of
ezetimibe with a
statin allowed a greater percentage of patients to achieve treatment goals established in NCEP guidelines. The safety and side-effect profile of
ezetimibe plus
statin coadministration
therapy was generally comparable with that of
statin monotherapy. These studies establish
ezetimibe as an effective
lipid-lowering agent, which will likely be useful in the management of a broad range of patients with
hypercholesterolemia.
Ezetimibe can be used in conjunction with a
statin at the beginning of
therapy, or it can be added if patients do not achieve their
LDL-cholesterol goal with
statins alone.